Surrozen submits IND application for SZN-8141 to treat diabetic macular edema
Surrozen says it has submitted an IND application for SZN-8141 for the treatment of diabetic macular edema.
, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) NASDAQ:SRZN, a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic condition…